13.07.2018 - 07:02:33

SHOP APOTHEKE EUROPE N.V. takes over specialist for functional nutrition products nu3 GmbH, Berlin.


SHOP APOTHEKE EUROPE N.V. takes over specialist for functional nutrition products nu3 GmbH, Berlin.

Acquisition of a leading online company for superfoods and functional nutrition with a European presence. Complementary products and target groups enhance the positioning and economic value of SHOP APOTHEKE EUROPE. Financing by issuance of new shares and a cash payment. Founders and JAHR-Group, Hamburg, become shareholders of SHOP APOTHEKE EUROPE.

Venlo, the Netherlands, July 13, 2018. SHOP APOTHEKE EUROPE N.V. (the "Company" or "SHOP APOTHEKE EUROPE") has signed a contract yesterday to purchase all shares in nu3 GmbH, Berlin. SHOP APOTHEKE EUROPE Group acquired nu3 by means of an issue of a total of 54,470 new shares of SHOP APOTHEKE EUROPE in bearer form and an additional cash payment. The issuance of new shares and the exclusion of the pre-emptive rights in relation thereto has been approved by the supervisory board of the Company. In financial year 2017, nu3 GmbH achieved revenues of approximately EUR 30 million, of which approximately EUR 20 million were generated in European markets outside Germany. In addition to revenue increases for both companies in their core market Germany as well as in other European target markets such as France, SHOP APOTHEKE EUROPE expects faster and profitable growth in the coming years by leveraging synergies. With the acquisition of nu3 GmbH, SHOP APOTHEKE EUROPE further expands its positioning and value creation in its European markets: In addition to expanding the product range with complementary products, cross-selling potentials will emerge by addressing additional customers. nu3 GmbH is already active in major European markets and operates in the fast-growing market segment of functional nutrition products. The high-quality product range of nu3 which comprises natural food and health products, low carb products and sports nutrition has strong and well-known brands.

Michael Köhler, CEO of SHOP APOTHEKE EUROPE, explains: "nu3's business ideally complements our offering for the target group of health-conscious customers and provides us with the opportunity to grow even faster and with sustainable profitability, both in Germany and especially in our young markets such as France".

Dr. Robert Sünderhauf, founder and CEO of nu3 GmbH, adds: "We are looking forward to further expanding the attractive growth potential of the online market for superfoods and functional nutrition together with SHOP APOTHEKE EUROPE and to further strengthen the nu3 brand. The product ranges and customer groups as well as the European market presence perfectly complement each other".

The founders of nu3, who are significantly driving further expansion with SHOP APOTHEKE EUROPE, will become shareholders of SHOP APOTHEKE EUROPE together with the JAHR-Group, Hamburg.

Subject to the successful completion of the transaction, the management board of the Company intends to further specify the Group's growth forecast for the financial year 2018 with the publication of the half-year financial report on August 14, 2018 in accordance with the integration progress.  


SHOP APOTHEKE EUROPE is the leading and fastest growing online pharmacy in Continental Europe. With the acquisition of Europa Apotheek Venlo in November 2017, SHOP APOTHEKE EUROPE significantly extended its European market leadership with an expanded product range for the whole family in the areas of OTC, beauty and care products as well as prescription drugs.

SHOP APOTHEKE EUROPE already operates online pharmacies in Germany, Austria, France, Belgium, Italy, Spain and the Netherlands. In Germany, the TÜV-certified is the market leading. SHOP APOTHEKE EUROPE delivers a broad range of more than 100,000 original products to over 2.8 million active customers quickly and at attractive prices. In addition, SHOP APOTHEKE EUROPE provides comprehensive and consistent pharmaceutical services.

SHOP APOTHEKE EUROPE N.V. has been listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard) since 13 October 2016.  


Trade and public media: Sven Schirmer Mobile: +49 152 28 50 63 61 Email:

Financial media: Thomas Schnorrenberg Mobile: +49 151 46 53 13 17 Email:

Investor Relations: Dr. Ulrich Wandel Telephone: +31 77 850 6117 Email:


This announcement does not contain or constitute or form part of, and should not be construed as, an offer or invitation to sell, or the solicitation of an offer to buy or subscribe for, any securities of SHOP APOTHEKE EUROPE.

The distribution of this announcement and the offer and sale of the securities referred to herein may be restricted by law in certain jurisdictions and persons reading this announcement should inform themselves about and observe any such restriction. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.

This announcement is not for publication or distribution, directly or indirectly, in or into the United States, Australia, Canada or Japan or in any jurisdiction in which offers or sales of the securities referred to herein would be prohibited by applicable laws.

The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or the laws of any state within the United States or under the applicable securities laws of Australia, Canada or Japan, and may not be offered or sold in the United States, unless registered under the Securities Act or offered and sold in a transaction exempt from, or not subject to, the registration requirements of the Securities Act. The securities referred to herein are being offered and sold only outside the United States in "offshore transactions" as defined in and in accordance with Regulation S under the Securities Act. Subject to certain exceptions, the securities referred to herein may not be offered or sold in Australia, Canada or Japan or to, or for the account or benefit of, any national, resident or citizen of Australia, Canada or Japan. There will be no public offer of the securities referred to herein in the United States, Australia, Canada or Japan.

The offer referred to herein when made in member states of the European Economic Area (the "EEA") which have implemented the Prospectus Directive (each, a "Relevant Member State"), is only addressed to and directed at persons who are "qualified investors" (as defined in the Prospectus Directive (the "Qualified Investors")). For these purposes, the expression "Prospectus Directive" means Directive 2003/71/EC (and amendments thereto, including the 2010 PD Amending Directive), and includes any relevant implementing measure in the relevant member state and the expression "2010 PD Amending Directive" means Directive 2010/73/EU.

This announcement contains forward-looking statements that are subject to certain risks and uncertainties. The future financial results can significantly differ from the currently anticipated results as a result of various risks and uncertainties, including changes in the business, financial and competitive landscape, uncertainties related to legal disputes or investigations and the availability of funds. SHOP APOTHEKE EUROPE assumes no obligation to update the forward-looking statements included in this announcement.

13.07.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at

Language: English Company: SHOP APOTHEKE EUROPE N.V. Dirk Hartogweg 14 5928 LV Venlo

Netherlands Phone: 0800 - 200 800 300 Fax: 0800 - 90 70 90 20 E-mail: Internet: ISIN: NL0012044747, DE000A19Y072 WKN: A2AR94, A19Y07 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange   End of News DGAP News Service

704237  13.07.2018